. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: Kidney Int. 2013 Jun 5;84(6):1166–1175. doi: 10.1038/ki.2013.209

Table 2.

Thymosin β4 mRNA, POP Activity, and Ac-SDKP Concentration in Obstructed and Non-obstructed Contralateral Kidneys in WT Mice at Day 5 after UUO

	Thymosin β4 mRNA		POP Activity		Ac-SDKP
	Thymosin β4/GAPDH		(pmol/min^*mg tissue)		(pmol/mg tissue)
Treatment	Obs	CL	Obs	CL	Obs	CL
Control	10.81±0.89	1.29±0.27^†	27.60±2.26	40.10±2.97^†	1.40±0.19	2.41±0.22^†
POPi	10.97±1.33	1.34±0.24^†	2.06±0.26^*	12.68±1.30^*,^†	0.66±0.08^*	1.34±0.12^*,^†
Tβ4+POPi	9.14±0.68	1.27±0.26^†	5.73±1.59^*	18.35±1.42^*,^†	0.86±0.09^*	1.48±0.26^*,^†
Tβ4	13.76±2.88	0.86±0.22^†	21.18±1.61	46.88±3.51^†	1.09±0.12	1.94±0.19^†
Ac-SDKP	6.49±0.61^*	0.57±0.03 ^*,^†	31.88±1.18	25.40±2.63^*,^†	2.41±0.08^*	4.06±0.34^*,^†
Normal	0.73±0.15^#		31.39±3.20^††		2.13±0.31^#

Abbreviations: Obs, obstructed kidneys; CL, non-obstructed contralateral kidneys; POPi, POP inhibitor; Tβ4+POPi, thymosin β4 plus POP inhibitor; Tβ4, thymosin β4.

Data are mean ± SEM, n=5–8 in each group.

p<0.05 vs. its own control

^†

p<0.05 for the obstructed vs. the non-obstructed contralateral kidneys with same treatment

p<0.05 for normal kidneys vs. the control obstructed kidneys

^††

p<0.05 for normal kidneys vs. the control non-obstructed contralateral kidneys.